389 articles in this topic
Phase 1 trial shows MP0317 activates anti-tumor immunity in solid tumors with a favorable safety profile, supporting combination therapy.
RO7300490, a FAP-targeted CD40 agonist, proved manageable in 80 advanced cancer patients but produced no objective tumor responses despite clear immune activation.
A first-in-human trial shows CAR-modified stem cell memory T cells outperform standard CAR T cells in expansion, persistence, and complete responses.
New research shows that the level of RAS oncogene activity determines whether cells become senescent or tumorigenic β a key cancer-prevention insight.
A Danish cohort of 49,894 adults shows first-time seizures carry a 76-fold elevated risk of neurological cancer and double the risk of non-neurological cancers within one year.
Scientists discover that maintaining proteostasis in tumor-infiltrating lymphocytes prevents exhaustion and boosts immunotherapy outcomes.
A new agentic AI framework autonomously generates biological concepts from pathology images, identifying prognostic and predictive cancer biomarkers without manual feature engineering.
A novel cell-labeling tool reveals how ERΞ±+ macrophages create immune-excluded niches in bone, blocking T cells from destroying cancer.
A clinical trial in Nature Cancer shows an AI model meaningfully boosts diagnostic accuracy for lung nodules, a critical step in early cancer detection.
A 156-patient multimodal study reveals two distinct immune microenvironments in breast cancer brain metastases that predict survival and immunotherapy response.
A new AI model spots pancreatic cancer on standard CT scans nearly 16 months before radiologists can see it β with nearly 3x their sensitivity.
A 73-patient study finds PD-L1 expression and TERT mutations identify high-grade thyroid cancers most likely to benefit from checkpoint inhibitor therapy.
